The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald A, Schartl M, Goebeler M, Meierjohann S.
Appenzeller S, et al. Among authors: schrama d.
Cancer. 2019 Feb 15;125(4):586-600. doi: 10.1002/cncr.31843. Epub 2018 Dec 18.
Cancer. 2019.
PMID: 30561760
Free article.